Search

Your search keyword '"Inokuchi, Haruo"' showing total 14 results
Start Over Author "Inokuchi, Haruo" Search Limiters Full Text
14 results on '"Inokuchi, Haruo"'

1. Derived neutrophil-to-lymphocyte ratio has the potential to predict safety and outcomes of durvalumab after chemoradiation in non-small cell lung cancer

Author

Sugimoto, Akira, Kaneda, Hiroyasu, Yoshimoto, Naoki, Nagata, Kenji, Fujii, Tatsuo, Michimoto, Koichi, Ueno, Shunsuke, Kamimori, Takao, Ishii, Yoshie, Sakagami, Mai, Inokuchi, Haruo, Shibuya, Keiko, Mizutani, Megumi, Nagamine, Hiroaki, Nakahama, Kenji, Matsumoto, Yoshiya, Tani, Yoko, Sawa, Kenji, and Kawaguchi, Tomoya

Published
2024
Full Text
View/download PDF

5. Ten‐year outcomes of whole‐pelvic intensity‐modulated radiation therapy for prostate cancer with regional lymph node metastasis

Author

Nakamura, Kiyonao, primary, Norihisa, Yoshiki, additional, Ikeda, Itaru, additional, Inokuchi, Haruo, additional, Aizawa, Rihito, additional, Kamoto, Toshiyuki, additional, Kamba, Tomomi, additional, Inoue, Takahiro, additional, Yamasaki, Toshinari, additional, Akamatsu, Shusuke, additional, Kobayashi, Takashi, additional, Ogawa, Osamu, additional, and Mizowaki, Takashi, additional

Published
2022
Full Text
View/download PDF

6. Ten‐year outcomes of whole‐pelvic intensity‐modulated radiation therapy for prostate cancer with regional lymph node metastasis.

Author

Nakamura, Kiyonao, Norihisa, Yoshiki, Ikeda, Itaru, Inokuchi, Haruo, Aizawa, Rihito, Kamoto, Toshiyuki, Kamba, Tomomi, Inoue, Takahiro, Yamasaki, Toshinari, Akamatsu, Shusuke, Kobayashi, Takashi, Ogawa, Osamu, and Mizowaki, Takashi

Subjects
LYMPH node cancer, CANCER radiotherapy, LYMPHATIC metastasis, CASTRATION-resistant prostate cancer, PROSTATE cancer, ANDROGEN deprivation therapy, PELVIS
Abstract

Background: Management of pelvic node‐positive prostate cancer has been challenging and controversial. We conducted a study to evaluate the outcomes of whole‐pelvic (WP) simultaneous integrated boost (SIB) intensity‐modulated radiation therapy (IMRT) combined with androgen deprivation therapy (ADT). Methods: A total of 67 consecutive patients with cT1c‐4N1M0 prostate cancer were definitively treated by WP SIB‐IMRT. Neoadjuvant ADT (median: 8.3 months) was administered in all cases. WP SIB‐IMRT was designed to simultaneously deliver 78, 66.3, and 58.5 Gy in 39 fractions to the prostate plus seminal vesicles, metastatic lymph nodes (LNs), and the pelvic LN region, respectively. Adjuvant ADT (median: 24.7 months) was administered in 66 patients. Results: The median follow‐up period was 81.6 months (range: 30.5–160.7). Biochemical relapse‐free, overall, and prostate cancer‐specific survival rates at 10 years were 59.8%, 79.6%, and 86.3%, respectively. Loco‐regional recurrence was not observed. Being in International Society of Urological Pathology grade group 5 and having a posttreatment detectable nadir prostate‐specific antigen (PSA) level (≥0.010 ng/ml) were significantly associated with worse prostate cancer‐specific survival and progression of castration resistance. The 10‐year cumulative incidence rates of grade 2 and 3 late toxicities were, respectively, 1.5% and 0% for genitourinary, 0% and 1.5% for gastrointestinal events. No grade 4 acute or late toxicities were observed. Conclusions: WP SIB‐IMRT can be safely administered to patients with pelvic node‐positive prostate cancer. Since grade group 5 and detectable nadir PSA levels are risks for castration resistance, we may need to increase the intensity of treatment for such cases. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

13. Abstract 4677: Non-prostate cancer death within 5 years after radical therapy in men with localized prostate cancer.

Author

Kobayashi, Takashi, primary, Kamba, Tomomi, additional, Terada, Naoki, additional, Yamasaki, Toshinari, additional, Ikeda, Itaru, additional, Inokuchi, Haruo, additional, Norihisa, Yoshiki, additional, Mizowaki, Takashi, additional, Inoue, Takahiro, additional, Okubo, Kazutoshi, additional, Yoshimura, Koji, additional, Hiraoka, Masahiro, additional, and Ogawa, Osamu, additional

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results